AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27728850 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination
Number of subjects: 0
Study 24196521 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance circuit training (6 stations, 3 days per week for 12 weeks)
Number of subjects: 40
Study 24196521 — intervention group
Group type: COMPARATOR
Intervention: Control group (16 age-, sex-, and BMI-matched adults with Down syndrome)
Number of subjects: 40
Study 21641365 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg
Number of subjects: 864
Study 21641365 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 864
Study 21641365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 864
Study 19365563 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 151
Study 19365563 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 151
Study 16442926 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 70
Study 16442926 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group not explicitly mentioned)
Number of subjects: 70
Study 15234407 — intervention group
Group type: EXPERIMENTAL
Intervention: mibefradil 50 mg
Number of subjects: 30
Study 15234407 — intervention group
Group type: COMPARATOR
Intervention: mibefradil 100 mg/day
Number of subjects: 30
Study 15234407 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 11509483 — intervention group
Group type: EXPERIMENTAL
Intervention: Postocclusive reactive hyperemia in hypertensive subjects
Number of subjects: 52
Study 11509483 — intervention group
Group type: COMPARATOR
Intervention: Postocclusive reactive hyperemia in normotensive subjects
Number of subjects: 52
Study 11509483 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous occlusion in hypertensive subjects
Number of subjects: 52
Study 11509483 — intervention group
Group type: COMPARATOR
Intervention: Venous occlusion in normotensive subjects
Number of subjects: 52
Study 11509483 — intervention group
Group type: EXPERIMENTAL
Intervention: Postocclusive hyperemia in hypertensive subjects
Number of subjects: 52
Study 11509483 — intervention group
Group type: COMPARATOR
Intervention: Postocclusive hyperemia in normotensive subjects
Number of subjects: 52
Study 9210690 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefodizime
Number of subjects: 54
Study 9210690 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime
Number of subjects: 54
Study 8386969 — intervention group
Group type: EXPERIMENTAL
Intervention: Single magnetic coil (MC) pulses applied over human calcarine cortex
Number of subjects: 0
Study 8386969 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of 2 or 3 MC pulses at intervals of 0-60 ms or more than 140 ms after the visual stimulus
Number of subjects: 0
Study 8386969 — intervention group
Group type: EXPERIMENTAL
Intervention: First MC pulse delivered 120 ms or later, followed by a second MC pulse 40 ms later
Number of subjects: 0
Study 8386969 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptual recovery of 5-character words
Number of subjects: 0
Study 8386969 — intervention group
Group type: EXPERIMENTAL
Intervention: Random letters vs. arbitrary linear patterns
Number of subjects: 0
Study 3144919 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdermal estradiol pellets (25 mg, n = 10)
Number of subjects: 20
Study 3144919 — intervention group
Group type: COMPARATOR
Intervention: Transdermal estradiol patch (0.1 mg, n = 10)
Number of subjects: 20
Study 28479329 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophilic asthma
Number of subjects: 167
Study 28464935 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated implementation (receive outside assistance)
Number of subjects: 25
Study 28464935 — intervention group
Group type: COMPARATOR
Intervention: Standard implementation (receive minimal assistance)
Number of subjects: 25
Study 25547414 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S vaccination
Number of subjects: 291
Study 25547414 — intervention group
Group type: COMPARATOR
Intervention: Comparator vaccine
Number of subjects: 291
Study 22428541 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 consecutive cases of unilateral cleft lip repairs
Number of subjects: 39
Study 22428541 — intervention group
Group type: EXPERIMENTAL
Intervention: 27 consecutive cases of unilateral cleft lip repairs
Number of subjects: 39
Study 22428541 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative evaluations
Number of subjects: 39
Study 22428541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleft severity evaluations
Number of subjects: 39
Study 22428541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleft severity correlation with outcomes
Number of subjects: 39
Study 21255977 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutricia preOp (400 mL; 50.4 g carbohydrates; 260 mOsm/kg)
Number of subjects: 8
Study 21255977 — intervention group
Group type: COMPARATOR
Intervention: Roosvicee Original (400 mL; 48 g carbohydrates; 805 mOsm/kg)
Number of subjects: 8
Study 18976892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cast immobilization of the ankle
Number of subjects: 62
Study 18976892 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment with no immobilization
Number of subjects: 62
Study 22949472 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure variability (BPV) measured by various metrics (maximum, standard deviation, coefficient of variation, successive variation, standard deviation independent of mean, successive variation independent of mean)
Number of subjects: 720
Study 22949472 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure variability (BPV)
Number of subjects: 720
Study 15499622 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement (verum) containing plant estrogens, antioxidants, including carotenoids, selenium, administered for 6 weeks
Number of subjects: 37
Study 15499622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 15499622 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement (verum)
Number of subjects: 37
Study 12056038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cernilton
Number of subjects: 87
Study 12056038 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 87
Study 12056038 — intervention group
Group type: COMPARATOR
Intervention: BPH group
Number of subjects: 87
Study 12056038 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic prostatitis group
Number of subjects: 87
Study 9659026 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 G cannula
Number of subjects: 25
Study 9659026 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 G cannula
Number of subjects: 25
Study 9659026 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both cannulae
Number of subjects: 25
Study 7868459 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint training (2-3 times per week for 6 weeks)
Number of subjects: 11
Study 7868459 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint training
Number of subjects: 11
Study 7868459 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11
Study 2732892 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (50 mg) administered at 9 am
Number of subjects: 25
Study 2732892 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (50 mg) administered at 7 pm
Number of subjects: 25
Study 2732892 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered at 9 am
Number of subjects: 25
Study 2732892 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered at 7 pm
Number of subjects: 25
Study 2732892 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (50 mg) administered at both times
Number of subjects: 25
Study 2732892 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal levels measured before and after trial
Number of subjects: 25
Study 4920541 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 221
Study 30482192 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy (up to six individual sessions over 3 weeks)
Number of subjects: 51
Study 30482192 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 51
Study 28486023 — intervention group
Group type: EXPERIMENTAL
Intervention: rSO2 arm (transcranial oxygen saturation threshold > 60%)
Number of subjects: 102
Study 28486023 — intervention group
Group type: COMPARATOR
Intervention: hemoglobin arm (maintaining hemoglobin between 85 and 100 g/L)
Number of subjects: 102
Study 28486023 — intervention group
Group type: EXPERIMENTAL
Intervention: rSO2 arm
Number of subjects: 102
Study 28486023 — intervention group
Group type: COMPARATOR
Intervention: hemoglobin arm
Number of subjects: 102
Study 25063574 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular arrhythmia bursts (VABs)
Number of subjects: 154
Study 25063574 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcirculation (MBG 2/3) restoration
Number of subjects: 154
Study 25063574 — intervention group
Group type: EXPERIMENTAL
Intervention: VABs in patients with MBG 2/3
Number of subjects: 154
Study 25063574 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion VABs
Number of subjects: 154
Study 23465304 — intervention group
Group type: EXPERIMENTAL
Intervention: Postvisit contact by e-mail or telephone
Number of subjects: 1350
Study 23465304 — intervention group
Group type: COMPARATOR
Intervention: No postvisit contact (control)
Number of subjects: 1350
Study 23465304 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mail contact
Number of subjects: 1350
Study 23465304 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone contact
Number of subjects: 1350
Study 24800362 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin HCI 5 mg twice daily in addition to conventional treatment
Number of subjects: 60
Study 24800362 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Diclofenac sodium, Anti Spasmodic (Drotverine HCl), Proton Pump inhibitor (Omeprazole 20 mg) once daily)
Number of subjects: 60
Study 24800362 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin group
Number of subjects: 60
Study 24800362 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 18317253 — intervention group
Group type: EXPERIMENTAL
Intervention: APOE genotype disclosure
Number of subjects: 162
Study 18317253 — intervention group
Group type: EXPERIMENTAL
Intervention: Numerical lifetime risk estimates
Number of subjects: 162
Study 18317253 — intervention group
Group type: COMPARATOR
Intervention: Control (no genotype disclosure)
Number of subjects: 162
Study 17129496 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT with standardized house dust mite (HDM) vaccine
Number of subjects: 132
Study 17129496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 12840632 — intervention group
Group type: EXPERIMENTAL
Intervention: AA genotype
Number of subjects: 1720
Study 12840632 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper tertile of % high-intensity activity
Number of subjects: 1720
Study 12840632 — intervention group
Group type: COMPARATOR
Intervention: CETP 1b.‐629 x % high‐intensity activity interaction
Number of subjects: 1720
Study 11054330 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior incision group
Number of subjects: 87
Study 11054330 — intervention group
Group type: COMPARATOR
Intervention: Temporal incision group
Number of subjects: 87
Study 11054330 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 87
Study 8626986 — intervention group
Group type: EXPERIMENTAL
Intervention: Credit card asthma self-management plan
Number of subjects: 30
Study 1345134 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 194
Study 1345134 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hormone replacement therapy)
Number of subjects: 194
Study 6541538 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 102
Study 6541538 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 102
Study 6541538 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 102
Study 31375814 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect bonding technique
Number of subjects: 56
Study 31375814 — intervention group
Group type: COMPARATOR
Intervention: Direct bonding technique
Number of subjects: 56
Study 29997294 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral norovirus vaccine (single dose)
Number of subjects: 66
Study 29997294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 27542703 — intervention group
Group type: EXPERIMENTAL
Intervention: High-hydration (HiH) status (USG < 1.015)
Number of subjects: 50
Study 27542703 — intervention group
Group type: COMPARATOR
Intervention: Low-hydration (LoH) status (USG ≥ 1.015)
Number of subjects: 50
Study 27542703 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine specific gravity (USG)
Number of subjects: 50
Study 25601335 — intervention group
Group type: COMPARATOR
Intervention: Single fractions of 1.0 Gy applied two times a week, for a total dose of 6.0 Gy (total therapy time: 3 weeks)
Number of subjects: 240
Study 25601335 — intervention group
Group type: EXPERIMENTAL
Intervention: Single fractions of 0.5 Gy applied 3 times a week, for a total dose of 6.0 Gy (total therapy time: 4 weeks)
Number of subjects: 240
Study 23928902 — intervention group
Group type: EXPERIMENTAL
Intervention: Flublok® (trivalent influenza vaccine)
Number of subjects: 0
Study 23928902 — intervention group
Group type: COMPARATOR
Intervention: Flublok®
Number of subjects: 0
Study 21037989 — intervention group
Group type: EXPERIMENTAL
Intervention: Imprint cytology technique
Number of subjects: 273
Study 21037989 — intervention group
Group type: COMPARATOR
Intervention: Gram-stained smear
Number of subjects: 273
Study 21037989 — intervention group
Group type: COMPARATOR
Intervention: Rapid urease test
Number of subjects: 273
Study 21037989 — intervention group
Group type: COMPARATOR
Intervention: Culture methods
Number of subjects: 273
Study 21037989 — intervention group
Group type: COMPARATOR
Intervention: Combination of Gram-stained smear, rapid urease test, and culture methods
Number of subjects: 273
Study 18218297 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisture-resistant tablet (dextran formulation)
Number of subjects: 120
Study 18218297 — intervention group
Group type: COMPARATOR
Intervention: Standard tablet (lactose formulation)
Number of subjects: 120
Study 16608513 — intervention group
Group type: EXPERIMENTAL
Intervention: rt-PA 1 mg per lumen once per week
Number of subjects: 340
Study 16608513 — intervention group
Group type: COMPARATOR
Intervention: Heparin 5,000 units per ml as a catheter locking solution after each dialysis session
Number of subjects: 340
Study 16608513 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis of rt-PA as a locking solution
Number of subjects: 340
Study 14993717 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg misoprostol
Number of subjects: 120
Study 14993717 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg misoprostol
Number of subjects: 120
Study 11689299 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaping with visual feedback stimuli
Number of subjects: 0
Study 11689299 — intervention group
Group type: COMPARATOR
Intervention: Random reinforcement
Number of subjects: 0
Study 11689299 — intervention group
Group type: COMPARATOR
Intervention: Self-paced button pressing without reinforcement
Number of subjects: 0
Study 9145877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime monotherapy
Number of subjects: 12
Study 9145877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime and Ofloxacin combination therapy
Number of subjects: 12
Study 9145877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin monotherapy
Number of subjects: 12
Study 9145877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin and Cefotaxime combination therapy
Number of subjects: 12
Study 9145877 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 12
Study 7679532 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of urapidil b.i.d. for 3 weeks (group L)
Number of subjects: 214
Study 7679532 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg b.i.d. for 1 week followed by 30 mg b.i.d. for 2 weeks (group M)
Number of subjects: 214
Study 7679532 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg b.i.d. for 1 week followed by 45 mg b.i.d. for 2 weeks (group H)
Number of subjects: 214
Study 7679532 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 214
Study 3497380 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib capsular polysaccharide vaccine (Connaught)
Number of subjects: 85
Study 3497380 — intervention group
Group type: EXPERIMENTAL
Intervention: Hib capsular polysaccharide vaccine (Praxis)
Number of subjects: 85
Study 3497380 — intervention group
Group type: COMPARATOR
Intervention: Both vaccines (Connaught and Praxis)
Number of subjects: 85
Study 29506692 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT)
Number of subjects: 200
Study 29506692 — intervention group
Group type: COMPARATOR
Intervention: Aerobic Continuous Training (ACT)
Number of subjects: 200
Study 29506692 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AIT and ACT
Number of subjects: 200
Study 26889783 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin Olive Oil enriched with its own phenolic compounds (FVOO)
Number of subjects: 33
Study 26889783 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin Olive Oil complemented with thyme phenolic compounds (FVOOT)
Number of subjects: 33
Study 26889783 — intervention group
Group type: COMPARATOR
Intervention: Virgin Olive Oil (VOO)
Number of subjects: 33
Study 26215196 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion axillary lymph node dissection (ALND)
Number of subjects: 59
Study 26215196 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion axillary lymph node dissection (ALND) in T3+ group
Number of subjects: 59
Study 26215196 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion axillary lymph node dissection (ALND) in T1/T2 group
Number of subjects: 59
Study 26215196 — intervention group
Group type: EXPERIMENTAL
Intervention: ILCs meeting ACOSOG Z0011 criteria
Number of subjects: 59
Study 26215196 — intervention group
Group type: EXPERIMENTAL
Intervention: ILCs not meeting ACOSOG Z0011 criteria
Number of subjects: 59
Study 23885519 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 300 microg (group M, n=20)
Number of subjects: 60
Study 23885519 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 300 microg + bupivacaine 2 mg (group MB, n=20)
Number of subjects: 60
Study 23885519 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 300 microg + bupivacaine 2 mg + fentanyl 25 microg (group MBF, n=20)
Number of subjects: 60
Study 21180957 — intervention group
Group type: EXPERIMENTAL
Intervention: 2x/day fluoride dentifrice (FD)
Number of subjects: 12
Study 21180957 — intervention group
Group type: EXPERIMENTAL
Intervention: 2x/day fluoride dentifrice (FD) + 1x/day fluoride mouthrinse (FR)
Number of subjects: 12
Study 21180957 — intervention group
Group type: EXPERIMENTAL
Intervention: 3x/day fluoride dentifrice (FD)
Number of subjects: 12
Study 19034875 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg/day)
Number of subjects: 66
Study 19034875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 16845924 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural network algorithms (Standard Backpropagation, Scaled Conjugate Gradient, Backpropagation with Bayesian Regularization)
Number of subjects: 24
Study 16845924 — intervention group
Group type: EXPERIMENTAL
Intervention: Backpropagation with Bayesian Regularization (BR)
Number of subjects: 24
Study 16845924 — intervention group
Group type: EXPERIMENTAL
Intervention: Feature selection technique with BR
Number of subjects: 24
Study 14583862 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalbavancin (2 doses: 1100 mg IV once and 500 mg IV one week later)
Number of subjects: 62
Study 14583862 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalbavancin (1 dose: 1100 mg IV)
Number of subjects: 62
Study 14583862 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care regimen
Number of subjects: 62
Study 10881066 — intervention group
Group type: EXPERIMENTAL
Intervention: 750ml of 10% mannitol (Group M)
Number of subjects: 80
Study 10881066 — intervention group
Group type: COMPARATOR
Intervention: 180ml of sodium phosphate preparation (Group NaP)
Number of subjects: 80
Study 10881066 — intervention group
Group type: COMPARATOR
Intervention: Group NaP (sodium phosphate)
Number of subjects: 80
Study 10881066 — intervention group
Group type: EXPERIMENTAL
Intervention: Group M (mannitol)
Number of subjects: 80
Study 7722124 — intervention group
Group type: EXPERIMENTAL
Intervention: rt‐PA (0.03 mg/kg body weight per h for 3 consecutive days) plus heparin
Number of subjects: 67
Study 7722124 — intervention group
Group type: COMPARATOR
Intervention: heparin plus placebo
Number of subjects: 67
Study 1974506 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg once daily (o.d.)
Number of subjects: 131
Study 1974506 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg once daily (o.d.)
Number of subjects: 131
Study 7030149 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia
Number of subjects: 12
Study 7030149 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 12
Study 30587216 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactor™
Number of subjects: 16
Study 30587216 — intervention group
Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 16
Study 26880615 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (1.2 mg/kg)
Number of subjects: 10
Study 26880615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 26880615 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac (0.25 mg/kg)
Number of subjects: 10
Study 26880615 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (4.2 mg/kg)
Number of subjects: 10
Study 24716651 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery
Number of subjects: 20